

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this Examiner's Amendment was given in telephone interview with Joseph Williams on 4 January 2007. An examiner's amendment to the claims and the specification was discussed.

In the Claims:

Cancel Claim 8.

In claim 5, line 4, delete the word "and" between IL-11 and IL-12.

In claim 5, line 4, add a comma between IL-11 and IL-12.

Line ⁴ of Claim 5 to read: "IL-10, IL-11, IL-12, IGF-1, LIF...."

In the Specification:

Page 3, line 30, capitalize the trademarks ALBUGRANIN, NEULASTA, NEUPOGEN, and GRANOCYTE.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cherie M. Woodward whose telephone number is (571) 272-3329. The examiner can normally be reached on Monday - Thursday 9:00am-7:30pm (EST).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on (571) 272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

AmB
2/5/07